Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox) : a retrospective observational study in Lyon, France, June to August 2022
Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 27(2022), 50 vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Merad, Yanis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 26.01.2023 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2022.27.50.2200882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352060239 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352060239 | ||
| 003 | DE-627 | ||
| 005 | 20231227131106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2022.27.50.2200882 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM352060239 | ||
| 035 | |a (NLM)36695469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Merad, Yanis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox) |b a retrospective observational study in Lyon, France, June to August 2022 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Modified Vaccinia Virus Ankara | |
| 650 | 4 | |a Monkeypox | |
| 650 | 4 | |a Mpox | |
| 650 | 4 | |a Post-exposure | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Gaymard, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Cotte, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Perpoint, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaiate, Dulce |e verfasserin |4 aut | |
| 700 | 1 | |a Godinot, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Cannesson, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Batalla, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Oria-Yassir, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Landré, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Morfin, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Bouscambert, Maude |e verfasserin |4 aut | |
| 700 | 1 | |a Valour, Florent |e verfasserin |4 aut | |
| 700 | 1 | |a Ader, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, Anne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 27(2022), 50 vom: 01. Dez. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:50 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2022.27.50.2200882 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 50 |b 01 |c 12 | ||